Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.43 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12704573 | 0.86 | XPO1 (0.49) | HSD17B10MAPTCYP1A2HTTCYP3A4 | |
| SCHEMBL11945529 | 0.77 | CYP1A2 (0.67) | MAPTCYP1A2HTTNPSR1GAA | |
| SCHEMBL8134433 | 0.76 | XPO1 (0.50) | MAPTCYP1A2HTTCYP3A4CYP2C19 | |
| SCHEMBL7870381 | 0.68 | CYP1A2 (0.50) | HSD17B10MAPTCYP1A2HTTCYP3A4 | |
| SCHEMBL9351267 | 0.68 | CYP1A2 (0.68) | MAPTCYP1A2HTTNPSR1GAA | |
| SCHEMBL8131606 | 0.67 | XPO1 (0.55) | MAPTCYP1A2CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL20880336 | 0.67 | XPO1 (0.51) | MAPTCYP1A2NPSR1ALDH1A1 | |
| SCHEMBL7045420 | 0.66 | — | — | |
| SCHEMBL30694098 | 0.66 | — | — | |
| SCHEMBL8141682 | 0.66 | CYP1A2 (0.67) | MAPTCYP1A2HTTNPSR1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415357-B2 | Compounds with anti-cancer activity | CANBAS CO., LTD. (JP) | 2013-04-09 | — | — | US | disclosed |
| US-20110092514-A1 | COMPOUNDS WITH ANTI-CANCER ACTIVITY | CANBAS CO., LTD. (JP) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092514-A1 | COMPOUNDS WITH ANTI-CANCER ACTIVITY | CDKN1A, CDC25C, DDB1 | BRD4 882/4885KAT2B 2909/4885BRD9 992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.